Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma.
Authors
Khoja, LeilaLorigan, Paul C
Zhou, Cong
Lancashire, Matthew
Booth, Jessica
Cummings, Jeffrey
Califano, Raffaele
Clack, G
Hughes, Andrew
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester, UK.Issue Date
2012-12-06
Metadata
Show full item recordAbstract
The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic biomarkers. A total of 101 patients with metastatic cutaneous melanoma were recruited prospectively. CTC number was determined using the CellSearch platform and melanoma kits in samples taken at baseline and serially during treatment. CTC numbers ranged between 0 and 36 per 7.5 ml blood; 26% of patients had 2 CTCs. Baseline CTC number was prognostic for median overall survival (OS) in univariate analysis (2.6 vs. 7.2 months (P<0.011) for patients with 2 CTCs vs. <2 CTCs, respectively). In multivariate analysis, CTC number was an independent prognostic biomarker of OS (hazard ratio (HR) 2.403, 95% confidence interval (CI) 1.303-4.430, P=0.005). Patients receiving treatment in whom CTC number remained 2 CTCs during treatment had shorter median OS than those who maintained <2 CTCs (7 vs. 10 months, HR 0.34, 95% CI 0.14-0.81, log-rank test P=0.015). In conclusion, CTC number in metastatic cutaneous melanoma patients is prognostic for OS with a cutoff of 2 CTCs per 7.5 ml blood. CTC number measured before and throughout treatment provided additional prognostic information. Larger studies are warranted to confirm CTC biomarker utility in melanoma patients.Journal of Investigative Dermatology advance online publication, 6 December 2012; doi:10.1038/jid.2012.468.Citation
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. 2012: J Invest DermatolJournal
The Journal of Investigative DermatologyDOI
10.1038/jid.2012.468PubMed ID
23223143Type
ArticleLanguage
enISSN
1523-1747ae974a485f413a2113503eed53cd6c53
10.1038/jid.2012.468
Scopus Count
Collections
Related articles
- Circulating melanoma cells as a predictive biomarker.
- Authors: Karakousis G, Yang R, Xu X
- Issue date: 2013 Jun
- Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
- Authors: Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M
- Issue date: 2015 Dec
- Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
- Authors: Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C
- Issue date: 2012 Feb 10
- Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
- Authors: Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Rydén L
- Issue date: 2016 Jul 8
- Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
- Authors: Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M
- Issue date: 2015 Aug